Benuvia and CCRP Launch Integrated Platform for Controlled-Substance Therapeutics

Benuvia Operations, LLC has formed a strategic partnership with Cannovation Clinical Research Partners (CCRP) to create an integrated platform for the development of Schedule I–V therapeutics. This collaboration aims to provide a streamlined pathway for pharmaceutical and biotech sponsors, combining manufacturing, regulatory, and clinical services in a single framework.

The partnership marks a significant advancement in the industry, as it is described as the first fully integrated manufacturing and contract research platform dedicated to controlled substances. By aligning the expertise of both organizations, the initiative intends to address the complexities associated with developing cannabinoid, psychedelic, and emerging central nervous system (CNS) therapeutics.

Benuvia is recognized for its capabilities in controlled-substance manufacturing, analytical testing, and Chemistry, Manufacturing, and Controls (CMC) development. In contrast, CCRP brings extensive experience in preclinical and clinical research, regulatory strategy, and global trial execution. Together, they aim to offer sponsors a compliant route from early-stage development to commercial supply, effectively overcoming challenges presented by fragmented vendor ecosystems.

Streamlining Development Processes

The integrated platform is designed to eliminate barriers that can slow down the development of new therapies. According to Terry Novak, CEO of Benuvia, “Partnering with CCRP allows us to align GMP production with coordinated clinical and regulatory execution, eliminating many of the barriers that slow development and improving the speed and efficiency with which sponsors can advance these important medicines.”

The collaboration will facilitate smoother transitions from investigational new drug (IND) applications to clinical trials, as well as reduce timelines through harmonised compliance standards. Furthermore, the partnership offers access to global clinical trial networks spanning North America, Europe, and Latin America.

The platform encompasses DEA-licensed manufacturing for Schedule I–V compounds, including psilocybin, LSD, and DMT. Additionally, it provides commercialisation support, which is becoming increasingly vital as interest in psychedelic and cannabinoid-based treatments grows.

Meeting Rising Demand

As the demand for specialized infrastructure and compliance in the controlled-substance sector increases, Benuvia and CCRP are well-positioned to meet this need. Lisa Rich-Milan, CEO of CCRP, emphasized that the shared platform will enable a responsible and accessible route for advancing controlled-substance therapeutics.

This partnership not only reflects a commitment to enhancing the development of innovative therapies but also highlights the potential for significant impact on patient care and treatment options in the future. The collaboration underscores the importance of integrating manufacturing and regulatory processes to foster a more efficient and effective drug development landscape for Schedule I–V substances.

As the global landscape for controlled-substance therapeutics continues to evolve, the collaborative efforts of Benuvia and CCRP could pave the way for breakthroughs in areas that have historically faced stringent regulatory challenges.